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S UMMA R Y
BA C KG ROUND : Adults with suspected tuberculosis
(TB) in health facilities in Africa have a high risk of
death. The risk of death for adults with suspected TB at
community-level is not known but may also be high.
ME T HOD S : Adults reporting cough of 72 weeks
(coughers) during a household census of 19 936 adults
in a poor urban setting in Malawi were randomly
sampled and age-frequency matched with adults without
cough72 weeks (controls). At 12 months, participants
were traced to establish vital status, offered human
immunodeficiency virus (HIV) testing and investigated
for TB if symptomatic (sputum for Xpertw MTB/RIF,
smear microscopy and culture).
R E SU LT S : Of 345 individuals with cough, 245 (71%)
were traced, as were 243/345 (70.4%) controls. TB was
diagnosed in 8.9% (16/178) of the coughers and 3.7%
(7/187) of the controls (P ¼ 0.039). HIV prevalence
among coughers was 34.6% (56/162) and 18.8% (32/
170) in controls (P ¼ 0.005); of those who were HIV-
positive, respectively 26.8% and 18.8% were newly
diagnosed. The 12-month risk of death was 4.1% (10/
245) in coughers and 2.5% (6/243) in controls (P ¼
0.317).
CONC LU S I ON : Undiagnosed HIV and TB are common
among adults with chronic cough, and mortality is high
in this urban setting. Interventions that promote timely
seeking of HIV and TB care are needed.
K E Y WORD S : sub-Saharan Africa; epidemiology; pre-
sumed TB; human immunodeficiency virus
COUGH AND OTHER SYMPTOMS, including
fever, weight loss, night sweats and haemoptysis,
are used to define individuals with suspected tuber-
culosis (TB).1,2 Adults with suspected TB in health
facilities in Africa have a high short-term (6–12
months) risk of death.3,4 The risk of death among
adults with suspected TB at community level is not
known, but may also be high and related to
undiagnosed human immunodeficiency virus (HIV)
infection and TB.
In Blantyre City, Malawi, HIV prevalence among
the urban poor is high, at 18.5%,5 while TB
prevalence is 0.9%.6 Malawi has implemented a
highly successful antiretroviral therapy (ART) pro-
gramme. HIV testing and counselling services have
become increasingly available in health facilities in
Malawi since 2010.7 By mid-2014, over half of the
estimated 1 million people living with HIV in Malawi
were aware of their status, almost 550 000 of whom
were enrolled in ART or pre-ART care.8 HIV testing
for all patients with TB symptoms is international
policy and part of the national tuberculosis control
programme (NTP), but this patient group has not
been prioritised for provider-initiated testing and
counselling in the 2015–2020 Malawi National HIV
and AIDS Strategy, and the NTP policy has not yet
been consistently implemented.8–10
The aims of the present study were to investigate
vital status and the prevalence of diagnosed and
undiagnosed HIV and TB among adult community
members 1 year after enquiry about chronic cough in
a household enumeration survey in urban Blantyre,
Malawi. This study demonstrates the consequences of
poor health seeking for cough and emphasises the
need for combined HIV and TB screening at the
household level in sub-Saharan Africa.
METHODS
Study design
This was a prospective cohort study of adults (age
716 years) identified during a baseline household
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enumeration survey as part of a cluster randomised
trial of intensified HIV-TB prevention in Blantyre,
Malawi.11–13 In the parent trial, all adult household
residents of 28 community health worker catchment
areas were enumerated between March and August
2011, and these form the sampling frame for this
study.
Procedures at household enumeration
During household enumeration (first visit), a repre-
sentative of the household provided demographic
data and reported on the chronic cough status of all
adults. Household members with reported chronic
cough were not provided with individual patient
management as part of the survey, although commu-
nity-based TB and HIV testing services were intro-
duced shortly afterwards and leaflets advising the
investigation of chronic cough were left in all
households. HIV testing was available to residents
through an HIV self-testing intervention introduced
in the study area in 2012.11,13 Adults with chronic
cough had the opportunity of attending for routine
care at two primary care clinics in the study area.
Selection of participants
Random sampling with frequency matching by 10-
year age bands was used to select a sample of
enumerated household residents from two groups:
household residents with chronic cough at enumera-
tion (‘with baseline cough’) and household residents
without chronic cough at enumeration (‘controls’).
No other inclusion or exclusion criteria were applied
to participants for this study.
Procedures at second household visit
Twelve months after the baseline household enumer-
ation, the research assistants made a second visit.
With the help of community informants, the research
assistants traced the dwellings of the participants
using global positioning satellite (GPS) coordinates
and descriptions of physical address recorded at
baseline. For the second visit, participants were
classified as lost to follow-up if they were not
identified at their dwelling after three tracing
attempts.
At the second visit, research assistants ascertained
the participants’ vital status and, where possible,
interviewed surviving participants to determine
whether they had chronic cough or had initiated
anti-tuberculosis treatment in the previous 12
months. Questionnaires assessed exposure to biomass
fuels for cooking or heating, exposure to occupation-
al dusts (adapted from questionnaires by the Burden
of Obstructive Lung Disease Initiative, BOLD14) and
smoking.
Participants were screened for TB symptoms
(presence of any of cough, fever, night sweats or
weight loss). Participants reporting cough of any
duration were asked to submit two sputum samples
for TB diagnosis; samples were collected by research
assistants and delivered to the research laboratory.
Participants who reported cough were also asked to
attend a hospital out-patient clinic and were offered
transport reimbursement if they attended the clinic.
HIV testing and counselling was offered to all
participants, including those who reported that they
had previously been diagnosed as HIV-positive, with
referral to study HIV care clinics for ARTassessments
(CD4 and World Health Organization [WHO]
clinical staging assessments) for those testing positive.
Death of a participant was confirmed by inter-
viewing household members during the second
household visit and by comparison with a list of
deaths routinely collected by resident study commu-
nity informants. Research assistants used the WHO
verbal autopsy questionnaire to record the date of
death and any clinical events or illnesses preceding
death.15
Case definitions for tuberculosis
Bacteriologically confirmed TBwas defined as at least
one positive sputum smear microscopy sample, a
positive culture for Mycobacterium tuberculosis or a
positive Xpertw MTB/RIF (Cepheid, Sunnyvale, CA,
USA) result. Clinically diagnosed TB was defined as
report of anti-tuberculosis treatment without bacte-
riological confirmation, i.e., negative smear micros-
copy, culture and Xpert. TB cases were detected in
two ways: by report of a participant registering for
anti-tuberculosis treatment in routine care in the
interval between household enumeration and the
second household visit; and following TB screening
during the second household visit.
Laboratory methods
Sputum specimens were tested using fluorescence
smear microscopy (Primo Star iLEDe, Carl Zeiss
Microimaging, Oberkochen, Germany) and Xpert,
and underwent culture for TB using BACTECe
MGITe 960 (BD, Sparks, MD, USA). Following
Ziehl-Neelsen staining, acid-fast bacilli (AFB) posi-
tive cultures were confirmed as M. tuberculosis
complex if the MPT 64 antigen test (MGIT TBc
Identification test, BD) was positive, with microscop-
ic cording and compatible growth characteristics at
378C, at room temperature and at 458C, and on
Lo¨wenstein-Jensen medium containing p-nitroben-
zoate (PNB).
HIV testing was performed using the OraQuick
ADVANCE Rapid HIV 1/2 Antibody Test (OraSure
Technologies, Bethlehem, PA, USA) on oral fluid. The
Determine HIV 1/2 test (Abbott Laboratories, Abbott
Park, IL, USA) and Uni-Golde Recombigenw HIV-1/
2 test (Trinity Biotech, Wicklow, Ireland) were used
to confirm positive results.
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Statistical analyses
The primary study outcomes were risk of mortality at
2 and 12 months after baseline enumeration, and
prevalence of diagnosed and undiagnosed HIV and
TB at the second household visit. For sample size
calculation, we assumed a risk of mortality at 12
months after baseline enumeration of 5%3 among
participants with baseline cough and 1%16 among
controls. A total of 333 participants were needed in
each group to detect this difference with 80% power,
and a of 5%. We inflated sample size estimates by
20% to account for loss to follow-up; the final sample
size was 400 participants in each group. Data were
analysed using Stata 13.1 (StataCorp LP, College
Station, TX, USA).
Baseline characteristics were compared between
groups using the v2, Fisher’s exact or Wilcoxon rank
sum tests. The risk of death was expressed as the
proportion of adults who died at 2 and 12 months,
respectively, and differences in mortality between
groups were compared using the v2 test. A Kaplan-
Meier plot was used to depict survival in the two
groups. Time to death was calculated as the time from
the date of household enumeration to the date of
death or censored on the date 12 months after
household enumeration. Only participants with vital
status ascertained were included in the analyses.
Risk factors for death in adults with baseline cough
were investigated. These were demographic charac-
teristics at baseline and interval HIV and TB status.
Univariate analyses were performed to assess associ-
ations between covariates and the outcome. Variables
that were significant on univariate analysis (P , 0.1)
were included in the multivariate analyses. Sex and
age were considered confounders a priori and were
Figure 1 Recruitment and follow-up of participants. *Participants were not identified as
residents of the neighbourhood by household members or community informants.
†Bacteriologically confirmed TB was defined as at least one positive sputum smear microscopy
sample, positive culture for Mycobacterium tuberculosis or a positive Xpert result. GPS¼ Global
Positioning Satellite; TB¼ tuberculosis; HIV¼ human immunodeficiency virus.
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included in the multivariate model whether or not
they were significant on univariate analysis.
Ethical consideration
The study was approved by the College of Medicine
of Malawi Research & Ethics Committee, Blantyre,
Malawi. Written informed consent was provided by
all participants (or household member if the partic-
ipant had died) at the household follow-up visit.
RESULTS
Tracing of participants at second household visit
The study population consisted of 19 936 adults, 583
(2.9%) of whom had reported chronic cough at
household enumeration. Of the 400 participants with
baseline cough who were sampled, 345 had suffi-
ciently precise GPS coordinates to allow follow-up.
Simple random sampling reduced the number of
controls to 345 for parity with the number of
participants with baseline cough (Figure 1). At the
second household visit, 71% (245/345) of partici-
pants with baseline cough and 70.4% (243/345) of
controls were identified. The reasons for unsuccessful
tracing were participants moving away from place of
residence or not being identified as residents of the
study neighbourhood cluster by household members
or community informants (Figure 1).
Baseline characteristics
There were no significant differences in baseline
sociodemographic characteristics between partici-
pants with baseline cough and controls (Table 1).
Mortality at 2 and 12 months after baseline
enumeration
At 2 months after baseline enumeration, all-cause
mortality was 1.6% (4/245) among participants with
baseline cough and 0% (0/243) in controls (P ¼
0.123) (Table 2). At 12 months, all-cause mortality
was high in both groups: 4.1% (10/245) among
participants with baseline cough and 2.5% (6/243)
among controls (P ¼ 0.317). Causes of death are
Table 1 Baseline characteristics for participants with vital status ascertained
Characteristic
Participants with
baseline cough Controls
P valuen (%) n (%)
Total 245 (100) 243 (100)
Age, years, median [IQR] 33 [25–44] 35 [25–44] 0.984
15–24 58 (23.7) 54 (22.2) 0.690
25–34 72 (29.4) 67 (27.6)
35–44 54 (22.0) 65 (26.8)
745 61 (24.9) 57 (23.5)
Sex, male 122 (49.8) 117 (48.2) 0.716
Marital status* 0.266
Married or cohabiting 150 (61.2) 137 (56.4)
Never married 47 (19.2) 58 (23.9)
Widowed, separated, or divorced 44 (18.0) 39 (16.1)
Ever lost a spouse to death† 25 (10.2) 20 (8.2) 0.723
Highest education level‡ 0.286
No schooling 12 (4.9) 13 (5.4)
Primary education only 122 (49.8) 103 (42.4)
Secondary no MSCE 75 (30.6) 73 (30.0)
Secondary with MSCE 23 (9.4) 38 (15.6)
Higher education 10 (4.1) 14 (5.8)
Household characteristics
Number of persons/room§¶
62 184 (75.1) 170 (69.9) 0.108
3–4 51 (21.0) 60 (24.7)
.4 7 (2.9) 13 (5.4)
Household wealth quintile#** 0.493
1 (poorest) 43 (17.6) 50 (20.6)
2 (poorer than average) 39 (15.9) 51 (20.9)
3 (average) 44 (18.0) 42 (17.3)
4 (wealthier than average) 52 (21.2) 45 (18.5)
5 (least poor) 58 (23.7) 50 (20.6)
*Missing values for persons with baseline cough¼ 4, controls¼ 9.
†Missing values for persons with baseline cough¼ 5, controls¼ 6.
‡Missing values for persons with baseline cough¼ 3, controls¼ 2.
§Missing values for persons with baseline cough¼ 3, controls¼ 5.
¶ Including kitchen.
#Missing values for persons with baseline cough¼ 9, controls¼ 5.
**Adapted from a proxy means test developed based on regression analysis of the 1998 MIHS.
IQR¼ interquartile range; MSCE¼Malawi Secondary Certificate of Education; MIHS¼Malawi Integrated Household
Survey.
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presented in Table 2. Figure 2 shows Kaplan-Meier
estimates of risk and timing of mortality.
Risk factors for mortality among participants with
baseline cough
Being diagnosed with TB was associated with a four-
fold greater odds of death in the first 12 months after
adjusting for age, sex and ever having ‘lost a spouse to
death’ (adjusted OR 4.20, 95%CI 0.81–17.80, P ¼
0.082).
HIV prevalence at second household visit
At the second household visit, the number of
participants interviewed in person and offered HIV
testing was 51.6% (178/245) among participants
with baseline cough and 54.2% (187/243) among
Table 2 Mortality assessment, HIV and TB screening at household visit 2
Characteristic
Participants with
baseline cough Controls
P valuen/N (%) n/N (%)
Mortality
Died at 2 months after enumeration 4/245 (1.6) 0/243 0.123
Died at 12 months after enumeration 10/245 (4.1) 6/243 (2.5) 0.317
Causes of death at 12 months*
TB-HIV 2/245 (0.8) 4/243 (1.6) 0.499
TB-HIV unknown 1/245 (0.4) 0/243 1.000
Acute respiratory infection 1/245 (0.4) 0/243 1.000
Respiratory neoplasm 1/245 (0.4) 0/243 1.000
Stroke 1/245 (0.4) 0/243 1.000
Unspecified cardiac disease 1/245 (0.4) 1/243 (0.4) 1.000
Abortion-related death 1/245 (0.4) 1/243 (0.4) 1.000
Unknown 2/245 (0.4) 0/243 0.499
TB symptoms at visit 2
Cough, any duration† 43/178 (24.2) 14/187 (7.5) ,0.001
Fever 24/178 (13.5) 11/187 (5.9) 0.048
Night sweats 32/178 (18.0) 21/187 (11.2) 0.187
Weight loss 30/178 (16.9) 16/187 (8.6) 0.038
Any TB symptom‡ 82/178 (46.1) 48/187 (25.7) ,0.001
Access to HIV testing and ART
HIV-positive, on ART 32/178 (18.0) 23/187 (12.3) 0.019
HIV-positive, not on ART 9/178 (5.0) 3/187 (1.6)
New HIV-positive 15/178 (8.4) 6/187 (3.2)
HIV-negative 106/178 (59.6) 138/187 (73.8)
HIV unknown 16/178 (9.0) 17/187 (9.1)
TB disease at visit 2
All TB cases 16/178 (8.9) 7/187 (3.7) 0.039
TB diagnosed in routine care§
Bacteriologically confirmed TB 4/178 (2.3) 1/187 (0.5) 0.281
Clinical 6/178 (3.4) 4/187 (2.1)
No TB 168/178 (94.3) 182/187 (97.3)
Undiagnosed TB at visit 2
Bacteriologically confirmed TB 6/178 (3.4) 2/187 (1.1) 0.133
No TB 172/178 (96.6) 185/187 (98.9)
Smoking and dust exposure at visit 2
Cigarette smoking
Current smoking 15/178 (8.4) 18/187 (9.6) 0.443
Past smoking 15/178 (8.4) 13/187 (7.0)
Never smoked 142/178 (79.8) 154/187 (82.4)
Smoking pack years, median [IQR] 4.0 [1.5–9.5] 0.9 [0.1–7.0] 0.059
Household fuel source¶
Biomass fuels only 144/178 (80.9) 157/187 (84.0) 0.590
Both biomass fuels and electricity 7/178 (3.9) 5/187 (2.7)
Electricity only 20/178 (8.0) 15/187 (11.2)
Exposed to organic dusts# 6/178 (3.4) 6/187 (3.2) 0.995
Exposed to inorganic dusts** 15/178 (8.4) 18/187 (9.6) 0.923
*Cause determined using WHO interVA4 verbal autopsy tool for deaths in the community.
† Among adults with baseline cough who still had cough at 1 year, 32.6% (14/43) were diagnosed with HIV, 14% (6/43)
had TB and 9% (4/43) had both HIV and TB.
‡ Includes cough of any duration, fever, night sweats and weight loss
§ TB diagnosed in routine care in the interval between enumeration and household visit 2.
¶ Charcoal and wood were the most commonly used biomass fuels.
#Work in cotton factory and cereal milling.
**Work in construction, rock mining, steel and welding factory.
HIV¼human immunodeficiency virus; TB¼ tuberculosis; ART¼antiretroviral therapy; IQR¼ interquartile range; WHO¼
World Health Organization.
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controls (Figure 1). Uptake of HIV testing was 91%
overall. HIV prevalence at the second household visit
was 34.6% (56/162) among participants with base-
line cough compared to 18.8% (32/170) among
controls (P ¼ 0.001). Among those who were HIV-
positive, 73.2% (41/56) of the participants with
baseline cough and 81.3% (26/32) of the controls
already knew their HIV-positive status, and respec-
tively 57.1% (32/56) and 71.8% (23/32) were
already on ART (Table 2 and Figure 3).
Tuberculosis disease at second household visit
TB disease diagnosed in the interval between house-
hold enumeration and the second household visit was
5.6% (10/178) among participants with baseline
cough compared to 2.7% (5/187) among controls
(P¼0.281) (Table 2). The prevalence of undiagnosed
TB at the second household visit was 3.4% (6/178)
among participants with baseline cough compared to
1.1% (2/187) among controls (P ¼ 0.133) (Table 2
and Figure 3).
DISCUSSION
The main findings of this study were that there was a
high burden of HIV and TB among adults with
chronic cough and high 1-year mortality in both
adults with chronic cough and controls.
Figure 2 Kaplan-Meier plot of mortality in adults with baseline
cough and controls.
Figure 3 Care seeking for HIV and TB. In Panels A and B: HIVþ/ART¼ participants who knew
their HIV status but were not on ART; new HIV ¼ participants newly diagnosed as HIV-positive
during screening at second household visit. HIV ¼ human immunodeficiency virus; ART ¼
antiretroviral therapy;þ¼ positive;¼ negative; TB¼ tuberculosis.
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Mortality at 12 months follow-up was high even
among adults without chronic cough at baseline. TB
and ‘ever having lost a spouse to death’ were
important risk factors for death among adults with
chronic cough. HIV status was not ascertained at the
baseline survey, however, and the finding that ‘ever
having lost a spouse to death’ was associated with
four-fold greater odds of death among adults with
chronic cough suggests the probable role of HIV in
driving this high mortality. HIV/acquired immune-
deficiency syndrome accounted for 33.8–50.6% of all
deaths among people aged 15–59 years in Africa,
with TB being the main killer in people living with
HIV.17
The Joint United Nations Programme on HIV and
AIDS goal is that by 2020, 90% of all people living
with HIV should know their status, and that 90% of
these should be on ART.18 In the community studied,
the proportion of those with HIV who knew their
HIV-positive status was 73.2% among adults with
baseline cough and 81.2% among controls. This
represents both the achievements of the HIV pro-
gramme inMalawi as well as the testing interventions
by the local study, which provided access to self-
testing for HIV.5,11 Notably, however, only 57.1% of
HIV-positive adults with chronic cough were on ART,
compared to 71.9% of HIV-positive controls. Both
knowledge of HIV status and ART coverage were
thus suboptimal, and more so in participants who
reported chronic cough at baseline. There are
probably multiple reasons for not initiating ART
despite known HIV infection among our participants,
including loss to follow-up before ART initiation
despite eligibility.19 ART coverage at community
level can be improved by introducing novel HIV
interventions, for example HIV self-testing and home
initiation of ART.13 ART initiation criteria are
currently moving towards universal ART initiation,
irrespective of CD4 cell count.20
Importantly, the diagnosis of TB was also subop-
timal, with about a third of all TB cases in this cohort
not having been diagnosed previously. Factors that
contributed to delayed TB diagnosis and treatment
include low disease awareness, use of informal care
Table 3 Risk factors for mortality at 12 months follow-up among adults with baseline cough
Total Dead Univariate
P value*
Multivariate†
P value*n n (%) OR (95%CI) OR (95%CI)
Sex
Female 123 4 (3.3) 1 0.509 1 0.595
Male 122 6 (4.9) 1.54 (0.43–6.15) 1.46 (0.36–6.55)
Age, years
15–24 58 3 (5.2) 1 0.428 1 0.507
25–34 72 1 (1.4) 0.26 (0.01–2.88) 0.22 (0.01–1.98)
35–44 54 2 (3.7) 0.71 (0.09–4.42) 0.47 (0.05–3.25)
745 61 4 (6.6) 1.29 (0.27–6.78) 0.84 (0.14–5.10)
Marital status
Married or cohabiting 150 4 (2.7) 1 0.506
Never married 47 3 (6.4) 2.49 (0.48–11.70)
Widowed, separated, or divorced 44 2 (4.6) 1.74 (0.24–9.23)
Ever lost a spouse to death
No 215 6 (2.8) 1 0.075 1 0.089
Yes 25 3 (12.0) 4.14 (0.85–16.13) 4.53 (0.78–24.08)
Highest education level
No schooling 12 1 (8.3) 1 0.791
Primary education only 122 5 (4.1) 0.47 (0.07–9.43)
Secondary education or higher 108 4 (3.7) 0.42 (0.06–8.66)
Number of persons/room
62 184 7 (3.8) 1 0.656
72 58 3 (5.2) 1.38 (0.29–5.15)
Household wealth quintile
1 (poorest) 43 4 (9.3) 1 0.433
2 (poorer than average) 39 3 (7.7) 0.81 (0.15–3.93)
3 (average) 44 1 (2.3) 0.23 (0.01–1.61)
4 (wealthier than average) 52 2 (3.9) 0.39 (0.05–2.10)
5 (least poor) 58 0 (0.0) —
HIV†
Negative 113 4 (3.5) 1 0.907
Positive 61 3 (4.9) 1.41 (0.31–6.51)
Unknown 71 3 (4.2) 1.20 (0.26–5.54)
TB†
No 223 7 (3.1) 1 0.051 1 0.082
Yes 22 3 (9.1) 4.87 (1.16–20.39) 4.20 (0.81–17.80)
* Likelihood ratio test P values.
† Interval HIV and TB status; for participants who died, HIV and TB status collected from verbal autopsies and anti-tuberculosis treatment registers.
OR¼ odds ratio; CI¼ confidence interval; HIV¼ human immunodeficiency virus; TB¼ tuberculosis.
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providers and stigma attached to HIV-associated
TB.21,22 In Malawi, patients incur substantial costs
when accessing TB diagnosis: poor patients spent an
estimated 2.5 times their monthly income to obtain a
diagnosis.23 Costs arose from fees and drugs during
care seeking outside government facilities, transpor-
tation and food. In addition, patients lost an average
of 22 days from work. The need to generate
continuing income is a major barrier to timely access
of TB diagnosis, especially among men trying not to
miss work.24
There are a number of limitations to this study.
The vital status of 30% of participants in each group
was not ascertained at 12 months follow-up.
However, loss to follow-up due to missed deaths
was minimised by the presence of key informants
who routinely conducted verbal autopsies. HIV
screening and ART eligibility were not offered
during the baseline survey; this was a missed
opportunity both for facilitated access to care and
for us to successfully investigate HIV status as a risk
factor for death. Our ability to ascertain care-
seeking pathways was limited by recall, given the
long interval between the first and second household
visits. Lung function assessment was not conducted,
and causes of chronic cough other than TB were not
thoroughly investigated.
CONCLUSION
Mortality at 1 year was high both in adults with and
in those without chronic cough, and the HIVand TB
burden in adults with chronic cough was signifi-
cantly higher, including undiagnosed disease.
Chronic cough should be considered an important
symptom for entry into HIV testing and care, and
efforts must be made to provide HIV diagnosis for
adults with symptoms of TB identified during
population-level activities such as systematic TB
screening or TB prevalence surveys.
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R E S U M E
CONT EX T E : Les adultes avec une tuberculose (TB)
pre´sume´e dans les structures de sante´ d’Afrique ont un
risque e´leve´ de de´ce`s. La magnitude du risque de de´ce`s
des adultes avec une TB soupc¸onne´e au niveau
communautaire n’est pas connue, mais elle est peut-
eˆtre e´leve´e.
M E´ T H O D E : Les adultes signalant une toux 72
semaines (tousseurs) lors d’un recensement a` domicile
de 19 936 adultes dans un contexte urbain pauvre du
Malawi ont e´te´ se´lectionne´s au hasard et apparie´s sur
l’aˆge a` des adultes sans toux 72 semaines (te´moins). A
12 mois, les participants ont e´te´ recherche´s afin
d’e´valuer leur e´tat de sante´, de leur proposer un test
pour le virus de l’immunode´ficience humaine (VIH) et de
rechercher une TB (crachats pour Xpertw MTB/RIF,
microscopie de frottis et culture) en cas de symptoˆmes.
R E´ S U LTAT S : Ont e´te´ retrouve´s 71% des tousseurs
(245/345) et 70,4% (243/345) des te´moins. Une TB a
e´te´ diagnostique´e chez 8,9% (16/178) des tousseurs et
3,7% (7/187) des te´moins (P¼0,039). La pre´valence du
VIH parmi les tousseurs a e´te´ de 34,6% (56/162) et de
18,8% (32/170) chez les te´moins (P¼0,005) ; parmi les
sujets VIH positifs, respectivement 26,8% et 18,8% ont
e´te´ des diagnostics nouveaux. Le risque de de´ce`s sur 12
mois a e´te´ de 4,1% (10/245) chez les tousseurs et de
2,5% (6/243) chez les te´moins (P¼ 0,317).
CONC LU S I ON : Une infection a` VIH et une TB non
diagnostique´es sont fre´quentes parmi les adultes atteints
de toux chronique, et la mortalite´ est e´leve´e dans ce
contexte urbain. Des interventions qui promeuvent la
recherche pre´coce du VIH et la prise en charge de la TB
sont ne´cessaires.
R E S UM E N
MARCO DE R E F E R ENC I A: Los pacientes adultos con
sospecha clı´nica de tuberculosis (TB) en los
establecimientos de salud en A´frica exhiben un alto
ı´ndice de mortalidad. No se conoce esta tasa en las
personas con presuncio´n de TB en la comunidad, pero
tambie´n podrı´a ser alta.
M E´ TODOS: Se practico´ un muestreo aleatorizado de los
adultos que referı´an tos de 72 semanas de duracio´n
(tosedores) durante un censo domiciliario de 19 936
adultos en un entorno urbano de escasos recursos de
Malawi y se emparejaron por frecuencia de edad con
adultos que no referı´an este antecedente (testigos). A los
12 meses, se localizaron los participantes con el fin de
verificar su estado vital, ofrecer la prueba diagno´stica de
la infeccio´n por el virus de la inmunodeficiencia humana
(VIH) y en caso de presentar sı´ntomas, investigar la TB
(muestra de esputo para la prueba Xpertw MTB/RIF, la
baciloscopia y el cultivo).
R E SU LTADOS: Se localizo´ el 71% (245/345) de los
tosedores y el 70,4% (243/345) de los testigos. Se
establecio´ el diagno´stico de TB en el 8,9% (16/178) de
los tosedores y el 3,7% (7/187) de los testigos (P ¼
0,039). La prevalencia de infeccio´n por el VIH en los
tosedores fue 34,6% (56/162) y en los testigos fue
18,8% (32/170) (P¼0,005); la seropositividad frente al
VIH en el 26,8% de los tosedores y el 18,8% de los
testigos correspondio´ a un diagno´stico nuevo. El riesgo
de muerte a los 12 meses fue 4,1% (10/245) en los
tosedores y 2,5% (6/243) en los testigos (P¼ 0,317).
CONC LU S I O´ N: La infeccio´n por el VIH y la TB no
diagnosticadas son frecuentes en los adultos que
presentan tos cro´nica y su mortalidad es alta en este
entorno. Se precisan intervenciones que favorezcan la
bu´squeda oportuna de casos.
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